Samsung Biologics' 'ESG Management' Included in Dow Jones World Index for 3 Consecutive Years

Samsung Biologics announced on the 11th that it has been included in the Dow Jones Sustainability Indices World, a global ESG (Environmental, Social, and Governance) representative evaluation index, for three consecutive years.

2023 Samsung Biologics ESG Report Cover Image [Photo by Samsung Biologics]

The Dow Jones Sustainability Indices World is a global ESG evaluation index published by S&P Global in the United States. It consists of the top 10% of companies in terms of economic performance and ESG performance among approximately 2,500 publicly traded companies with the highest market capitalization worldwide.

Samsung Biologics has been included in this World Index for three consecutive years since 2021, recognizing its efforts in ESG management. In particular, this year, its efforts toward carbon neutrality (Net Zero) in the environmental sector received high evaluations, earning the highest rating, which corresponds to the top 1% within the life sciences services sector.

In November last year, Samsung Biologics declared its 2050 Net Zero goal and announced a roadmap. Through this, it has achieved results such as reducing operational and manufacturing energy compared to 2021, improving infrastructure for building eco-friendly workplaces by using solar energy and purchasing renewable energy. Additionally, it is expanding global climate crisis response initiatives, including risk and opportunity analysis through the publication of the Task Force on Climate-related Financial Disclosures (TCFD) report and participation in the Sustainable Market Initiative (SMI). Furthermore, it is strengthening ESG management by sector to leap forward as a sustainable company.

In the Social sector, Samsung Biologics is striving to enhance human rights management throughout its operations by conducting human rights impact assessments in line with the advancement of the human rights governance system to manage potential human rights risks. Moreover, it is expanding ESG activities across the entire value chain through the expansion of supply chain ESG evaluations.

In the Governance sector, Samsung Biologics has established an ESG management system and strengthened accountability by operating an ESG Committee and establishing a dedicated ESG group. Through ISO37001 certification, it has established an anti-corruption management system and focused on enhancing the independence and transparency of the board of directors by forming committees and boards centered on outside directors.

John Rim, President of Samsung Biologics, said, “As the world’s No. 1 Contract Development and Manufacturing Organization (CDMO), we will write a model case of ESG management that successfully achieves carbon neutrality while growing together with stakeholders,” adding, “We will establish ourselves as an ESG leading company that leads the bio and pharmaceutical industry.”